Tag Archives: Infectious disease
Medicago Inc. and Mitsubishi Tanabe Pharma Corporation Enter into a Strategic Alliance to Develop New Vaccines
Medicago to Receive up to $33 Million in Upfront and Milestone Payments as well as Royalties under a First Agreement to Develop a Rotavirus Vaccine
Zambia / Counterfeit Medicines / Five Mobile Compact Labs to Detect Counterfeit Medicines Presented to Zambia
One million children at risk of life-threatening malnutrition in Sahel region – $67 million needed for immediate relief efforts
SEATTLE, Jan. 31, 2012 /PRNewswire-USNewswire/ — The Infectious Disease Research Institute (IDRI) announced its technical support of the Sabin Vaccine Institute’s (Sabin) first ever Phase 1 clinical trial of a human hookworm vaccine candidate, which began last week in Brazil. The trial is a very significant and a critical step toward developing a vaccine that would reduce the global burden of human hookworm by providing effective long-term protection for those who are most at risk.
QUEBEC CITY, Jan. 19, 2012 /PRNewswire/ – Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully completed initial studies towards the development of a new VLP vaccine candidate for rabies. Over the past 12 months, as part of the Company’s strategy to further develop a pipeline of products, Medicago has been working diligently to expand the application of its VLP technology to new vaccine targets. Several research-stage products have demonstrated positive results, and the Company is working to advance selected targets into preclinical development, including its rabies vaccine.